Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Final Analysis of the Daliah Trial: A Randomized Phase III Trial of Interferon-α Versus Hydroxyurea in Patients with MPN

Blood (2023) 142 (Supplement 1): 746.

https://doi.org/10.1182/blood-2023-173127

Published: 2023

Journal Articles

Quality of Life and Symptom Burden of Patients with MPN during Treatment with Hydroxyurea or Pegylated Interferon-alpha2: Results from a Randomized Controlled Trial

Blood (2022) 140 (Supplement 1): 1794–1796.

https://doi.org/10.1182/blood-2022-156445

Published: 2022

Journal Articles

Genomic Profiling of a Phase III Clinical Trial of Interferon Versus Hydroxyurea in MPN Patients Reveals Mutation-Specific and Treatment-Specific Patterns of Response

Blood (2019) 134 (Supplement_1): 4202.

https://doi.org/10.1182/blood-2019-126164

Published: 2019

Journal Articles

Long-Term Efficacy and Safety of Recombinant Interferon Alpha-2 Vs. Hydroxyurea in Polycythemia Vera: Preliminary Results from the Three-Year Analysis of the Daliah Trial - a Randomized Controlled Phase III Clinical Trial

Blood (2018) 132 (Supplement 1): 580.

https://doi.org/10.1182/blood-2018-99-111255

Published: 2018

Journal Articles

No Development of Neutralizing Antibodies Against Recombinant Interferon-Alpha in Ph-Negative Myeloproliferative Neoplasms - a Prospective Study

Lukas Frans Ocias, Dennis Lund Hansen, Thomas Kielsgaard Kristensen, Karin de Stricker, Daniel El Fassi, MD PhD, Jesper Stentoft, Jørn Starklint, Mikael Frederiksen, Marianne Tang Severinsen, Ole Weis Bjerrum, MD DMSc, Peter Møller, Torben Mourits-Andersen, MD, Ulrik Malthe Overgaard, Hans Carl Hasselbalch, MD Professor, DMSc, Klaus Bendtzen, Thomas Stauffer Larsen, MD PhD

Blood (2015) 126 (23): 5177.

https://doi.org/10.1182/blood.V126.23.5177.5177

Published: 2015

Journal Articles

Safety and Efficacy of Combination Therapy of Interferon-Alpha2 + JAK1-2 Inhibitor in the Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Preliminary Results from the Danish Combi-Trial - an Open Label, Single Arm, Non-Randomized Multicenter Phase II Study

Stine Ulrik Mikkelsen, MD, Lasse Kjær, MSc, PhD, Vibe Skov, MSc, PhD, Mads Emil Bjørn, MD PhDStudent, Christen Lykkegaard Andersen, MD PhD, Ole Weis Bjerrum, MD DMSc, Nana Brochmann, MD PhDStudent, Daniel El Fassi, MD PhD, Torben A Kruse, Professor, PhD, Thomas Stauffer Larsen, MD PhD, Torben Mourits-Andersen, MD, Claus Henrik Nielsen, MD Professor, DMSc, Niels Pallisgaard, MSc, Mads Thomassen, MSc, PhD, Hans Carl Hasselbalch, MD Professor, DMSc

Blood (2015) 126 (23): 824.

https://doi.org/10.1182/blood.V126.23.824.824

Published: 2015

Journal Articles

Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia

Sif Gudbrandsdottir, Henrik Sverre Birgens, Henrik Frederiksen, Bjarne Anker Jensen, Morten Krogh Jensen, Lars Kjeldsen, Tobias Wirenfeldt Klausen, Herdis Larsen, Hans Torben Mourits-Andersen, Claus Henrik Nielsen, Ove Juul Nielsen, Torben Plesner, Stanislaw Pulczynski, Inge Helleberg Rasmussen, Dorthe Rønnov-Jessen, Hans Carl Hasselbalch

Blood (2013) 121 (11): 1976–1981.

https://doi.org/10.1182/blood-2012-09-455691

Published: 2013

Includes: Supplemental data

Journal Articles

A Phase II Study of Vorinostat (MK-0683) in Patients with Polycythemia Vera and Essential Thrombocythemia

Blood (2012) 120 (21): 803.

https://doi.org/10.1182/blood.V120.21.803.803

Published: 2012

Journal Articles

A New Simplified Prognostic Index with Age Cut-off of 70 Years for Patients with Diffuse Large B-Cell Lymphoma. A Population-Based Analysis From the Danish Lymphoma Registry, LYFO

Anne Ortved Gang, Michael Pedersen, MD, Francesco d'Amore, Lars Møller-Pedersen, MD, PhD, Bo Amdi Pedersen, Paw Jensen, Bjarne Bach Pedersen, Michael B. Møller, MD, DMSc, Ole Gadeberg, Steen Ingeberg, Torben mourits-Andersen, MD, Stanislaw Pulczynski, Tobias Wirenfeldt Klausen, Peter De Nully Brown

Blood (2012) 120 (21): 3651.

https://doi.org/10.1182/blood.V120.21.3651.3651

Published: 2012

Journal Articles

Epidemiological and Clinico-Pathological Features of Systemic Peripheral T-Cell Lymphomas (PTCL): A Population-Based Analysis from the Danish Lymphoma Registry LYFO

Francesco d’Amore, MD, Peter de Nully Brown, Lars Moeller Pedersen, Anne Bukh, Per Boye Hansen, Bjarne Bach Pedersen, Ole Gadeberg, Michael Pedersen, Steen Ingeberg, Stanislaw Pulczynski, Torben Mourits Andersen, Michael Moeller

Blood (2008) 112 (11): 3766.

https://doi.org/10.1182/blood.V112.11.3766.3766

Published: 2008

Journal Articles

Darbepoetin Alfa for the Treatment of Anemia in Patients with Myelofibrosis with Myeloid Metaplasia (MMM). Results from a Danish Multicenter Study.

Kathrine Hannestad, Thomas Stauffer Larsen, Torben Mourits Andersen, Niels Aage Toeffner Clausen, Per Boye Hansen, Bjarne Anker Jensen, Henrik Sverre Birgens, Hans Carl Hasselbalch

Blood (2007) 110 (11): 4641.

https://doi.org/10.1182/blood.V110.11.4641.4641

Published: 2007

Journal Articles

A Phase II Trial of Pegylated Interferon α-2b in Polycythemia Vera and Essential Thrombocythemia. Clinical Responses, Effects on PRV-1 Expression and Impact on Quality of Life.

Jan Samuelsson, MD, PhD, Hans Hasselbalch, Oystein Bruserud, Heike Pahl, Mats Merup, Olle Linder, Yvonne Brandberg, Poul Gram-Hansen, Magnus Bjorkholm, Waleed Ghanima, Claes Malm, Berit Markevarn, Torben Mourits-Andersen, Peter Johansson, Lars Nilsson, Gunnar Birgegard

Blood (2004) 104 (11): 1518.

https://doi.org/10.1182/blood.V104.11.1518.1518

Published: 2004

NARROW

Final Analysis of the Daliah Trial: A Randomized Phase III Trial of Interferon-α Versus Hydroxyurea in Patients with MPN

Quality of Life and Symptom Burden of Patients with MPN during Treatment with Hydroxyurea or Pegylated Interferon-alpha2: Results from a Randomized Controlled Trial

Genomic Profiling of a Phase III Clinical Trial of Interferon Versus Hydroxyurea in MPN Patients Reveals Mutation-Specific and Treatment-Specific Patterns of Response

Long-Term Efficacy and Safety of Recombinant Interferon Alpha-2 Vs. Hydroxyurea in Polycythemia Vera: Preliminary Results from the Three-Year Analysis of the Daliah Trial - a Randomized Controlled Phase III Clinical Trial

No Development of Neutralizing Antibodies Against Recombinant Interferon-Alpha in Ph-Negative Myeloproliferative Neoplasms - a Prospective Study

Safety and Efficacy of Combination Therapy of Interferon-Alpha2 + JAK1-2 Inhibitor in the Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Preliminary Results from the Danish Combi-Trial - an Open Label, Single Arm, Non-Randomized Multicenter Phase II Study

Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia

A Phase II Study of Vorinostat (MK-0683) in Patients with Polycythemia Vera and Essential Thrombocythemia

A New Simplified Prognostic Index with Age Cut-off of 70 Years for Patients with Diffuse Large B-Cell Lymphoma. A Population-Based Analysis From the Danish Lymphoma Registry, LYFO

Epidemiological and Clinico-Pathological Features of Systemic Peripheral T-Cell Lymphomas (PTCL): A Population-Based Analysis from the Danish Lymphoma Registry LYFO

Darbepoetin Alfa for the Treatment of Anemia in Patients with Myelofibrosis with Myeloid Metaplasia (MMM). Results from a Danish Multicenter Study.

A Phase II Trial of Pegylated Interferon α-2b in Polycythemia Vera and Essential Thrombocythemia. Clinical Responses, Effects on PRV-1 Expression and Impact on Quality of Life.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only